ACVR2A and pulmonary arterial hypertension: The recently FDA-approved PAH therapy Sotatercept, consisting of a fusion protein combining activin receptor type IIA with the Fc domain of human IgG1, operates by binding free activins, the ligands for ACTRIIA/B, thereby rebalancing SMAD signaling and promoting antiproliferation.